The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | Pre-treatment PET scans
Here, Paolo Strati, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the benefits of pre-treatment PET scans to identify areas of risk for transformation to large B-cell lymphomas and the significance of baseline maximum standardized uptake values (SUVmax). This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
